Here’s what you should know:
1. The company’s revenues increased 6 percent year-over-year.
2. U.S. revenues also increased 7 percent accounting for $2.9 billion of the total revenues.
3. Bristol-Myers Squibb’s Opdivo and Eliquis had strong sales over the quarter contributing to the increased revenues.
4. The company’s net earnings were $916 million, or $0.56 per share.
5. Concerning rest-of-year outlooks, Bristol-Myers Squibb decreased its earnings per share range estimates from $2.72 to $2.87 originally to $2.66 to $2.76.
More articles on gastroenterology:
Eisai submits liver cancer treatment application to FDA — 5 notes
GI center to know: Illinois Gastroenterology Institute
Capital Digestive Care adds 2 physicians & more: 5 GI practices in the news
